Colorectal Cancer
Conditions
Keywords
fruquintinib, Trifluridine/tipiracil, Microsatellite Stable, metastatic colorectal cancer
Brief summary
Colorectal cancer (CRC) is the fourth leading cause of cancer death worldwide, claiming approximately 900,000 lives annually. In China, CRC has become one of the top three most common cancers, with about 555,000 new cases and 286,000 deaths reported in 2020. For patients with advanced metastatic colorectal cancer (mCRC), chemotherapy remains the main treatment approach. While first and second-line treatments have improved survival rates, treatment options become very limited after these initial therapies fail. Current third-line options include single-drug treatments with fruquintinib, regorafenib, or Trifluridine/Tipiracil(TAS-102). Although these medications can extend survival, their effectiveness still needs improvement. Additionally, approximately 95% of mCRC patients have a tumor type \[Proficient Mismatch Repair(pMMR)/Microsatellite Stable(MSS)\] that responds poorly to immunotherapy alone, making it crucial to find ways to expand the benefits of immunotherapy to more patients. This study aims to evaluate the effectiveness and safety of combining: Fruquintinib (a targeted therapy) Immune checkpoint inhibitors (immunotherapy) TAS-102 (oral chemotherapy)in patients with unresectable metastatic colorectal cancer who have failed standard second-line treatments. By exploring combination therapy strategies, this research hopes to improve treatment response rates, extend overall survival and provide new treatment options for patients with limited choices
Interventions
DRUGFruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
DRUGFruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Fully informed about this study and voluntarily signed the informed consent form; * Age 18-75 years (inclusive); * Histologically confirmed unresectable metastatic colorectal cancer; * Confirmed pMMR (proficient mismatch repair) status without protein loss, as determined by:PCR testing showing microsatellite stable (MSS) or low microsatellite instability (MSI-L), OR Immunohistochemistry (IHC) demonstrating intact DNA mismatch repair (MMR) protein expression (including MLH1, MSH2, MSH6, and PMS2); * Failed or intolerant to two prior lines of standard systemic therapy for metastatic colorectal cancer; * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * Body Mass Index (BMI) ≥18 kg/m²; * Life expectancy ≥3 months; * Adequate organ function as defined below (no blood components or growth factors allowed within 14 days prior to enrollment): * Hematologic Function: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; White blood cell count (WBC) ≥4.0×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; -Hepatic Function: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN; -Renal Function: Blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN; Creatinine clearance (CCr) ≥50 mL/min; -Cardiac Function: Left ventricular ejection fraction (LVEF) ≥50%; QT interval corrected by Fridericia's formula (QTcF) \<470 ms; -Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤1.5×ULN; * Women of childbearing potential must use effective contraception; * Good compliance and willing to cooperate with follow-up visits.
Exclusion criteria
* Unable to comply with the study protocol or study procedures; * Prior treatment with TAS-102 (trifluridine/tipiracil); * Prior treatment with VEGFR inhibitors; * Prior treatment with immune checkpoint inhibitors; * Concurrent use of any other investigational drugs, or participation in another clinical trial with investigational drug treatment within 4 weeks prior to enrollment; * Vaccination with inactivated vaccines within 4 weeks prior to enrollment or planned vaccination during the study period; * Major surgery, severe traumatic injury, fracture, or ulcer within 4 weeks prior to enrollment; * Blood transfusion, blood products, or hematopoietic factors (such as albumin, granulocyte colony-stimulating factor \[G-CSF\], etc.) within 28 days prior to enrollment; * Alcohol or drug abuse within 4 weeks prior to enrollment; * Any factors affecting oral drug administration; * Concurrent presence of any of the following conditions: * Uncontrolled hypertension, coronary artery disease, arrhythmia, or heart failure; * Uncontrolled severe concurrent infection resulting in disability; * Proteinuria ≥2+ (1.0 g/24 h); * Evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of severity; * Arterial/venous thromboembolic events within 12 months prior to first treatment, such as cerebrovascular accident (including transient ischemic attack), etc.; * Acute myocardial infarction, acute coronary syndrome, or coronary artery bypass grafting (CABG) within 6 months prior to first treatment; * Fracture or long-term unhealed wounds; * Coagulation dysfunction, bleeding tendency, or currently receiving anticoagulant therapy; * Evidence of central nervous system (CNS) metastasis, or accompanied by severe malignant pleural effusion or ascites; * Other malignancies within 5 years prior to enrollment, except for basal cell or squamous cell carcinoma of the skin after curative surgery, or carcinoma in situ of the cervix; * Active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment; * Prior allogeneic bone marrow transplantation or organ transplantation; * Known hypersensitivity to study drugs or any of their excipients; * Unresolved toxicities greater than CTCAE v5.0 Grade 1 from prior anti-cancer therapy, excluding alopecia, lymphopenia, and oxaliplatin-induced neurotoxicity ≤Grade 2; * Any other disease, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the investigator's judgment, provides reasonable suspicion that the patient has a condition unsuitable for the use of the study drug (e.g., epileptic seizures requiring treatment), or that would affect the interpretation of study results, or would place the patient at high risk; * Pregnant or breastfeeding women; * Any patient deemed unsuitable for enrollment in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RP2D | From enrollment to the end of treatment at 4 week | Recommended phase 2 dose |
| Overall Survival (OS) | Up to 36 months | Time from randomization/enrollment to death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress-free Survival (PFS) | Assessed every 8 weeks, up to 12 months | Time from randomization/enrollment to first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first |
| Objective Response Rate (ORR) | Tumor assessments performed at baseline, then every 8 weeks (±7 days) from the date of first dose until radiographic disease progression or death, assessed up to approximately 12 months | The proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) as their best overall response, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Duration of Response (DoR) | Up to 12 months | Time from first documented response (CR/PR) to disease progression or death |
| Incidence of AEs | by NCI-CTCAE v5.0. From first dose up to 30 days after last dose | Number and percentage of participants experiencing adverse events graded by NCI-CTCAE v5.0 |
| Incidence of SAEs | From informed consent up to 30 days after last dose | Number and percentage of participants experiencing serious adverse events |
| Number of participants with Laboratory abnormalities | From baseline up to 30 days after last dose | Incidence of clinically significant laboratory parameter changes per NCI-CTCAE v5.0 |
Countries
China
Outcome results
None listed